FDA Oncology Leaders Sketch Out New Trial Designs for Accelerated Approvals

FDA leaders in oncology want sponsors seeking accelerated approval (AA) for cancer drugs to use new trial designs that will make the whole process more efficient and ultimately safer for patients.
Source: Drug Industry Daily